!!Sold Down the River … Newly Released Pfizer Documents – Worse than you Expected

“Newly Released Pfizer Documents Reveal COVID Jab Dangers” – Analysis by Dr. Joseph Mercola


PDF: https://media.mercola.com/ImageServer/Public/2022/March/PDF/pfizer-documents-reveal-vaccine-dangers-pdf.pdf

[…] “What really happened in the first 90 days of the jab rollout? How many adverse events and different health problems? How many deaths? The first tranche of documents were released March 1, 2022, and it proves beyond any shadow of a doubt – we’ve been sold down the river!” […]

Should you be pressed for time, just read the ‘Story at-a-Glance’:


· A small batch of documents released by the U.S. Food and Drug Administration in mid-November 2021 revealed that in the first three months of the COVID jab rollout, Pfizer received 42,086 adverse event reports that included 1,223 deaths

· The first really large tranche of Pfizer documents — some 10,000 pages — was released by the FDA March 1, 2022. Included are nine pages of recorded side effects, about 158,000 different health problems in all

· An initial review of case report forms (CRFs) reveal significant data collection errors and anomalies

· Problems included patients entered into the “healthy population” group who were far from healthy; serious adverse event (SAE) numbers that were left blank; sample barcodes that were missing; at least one death of a patient the day before being listed as being at a medical checkup; and second doses that were administered outside the three-week protocol window. There also are questions as to whether participants were properly observed for an adequate amount of time; plus adverse events were listed as “not serious” despite extended hospital stay and much more

· A majority of the CRFs in this release were from Ventavia-run trial sites. Ventavia is currently facing a lawsuit brought by Brook Jackson, a former Ventavia regional director. Jackson was fired shortly after she brought concerns about potential data falsification and poor laboratory management to the attention of the FDA and higher-ups in the company

Leave a Reply